Inhibitors of HIV-induced downregulation of HLA class I
Inhibitors of HIV-induced downregulation of HLA class I
批准号:
8465183
负责人:
JUAN LAMA
金额:
$21.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-15 至 2014-04-30
关键词:
Acquired Immunodeficiency SyndromeAdenovirusesAdverse effectsAnimal ModelAnti-Retroviral AgentsAntigen PresentationAntiviral AgentsBiological AssayBiological AvailabilityCD8B1 geneCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChemicalsCytomegalovirusDNA Sequence RearrangementData AnalysesDevelopmentDown-RegulationDrug resistanceFamilyFlow CytometryFoundationsFrequenciesFutureGoalsHIVHIV InfectionsHerpesviridaeHerpesvirus 1Highly Active Antiretroviral TherapyHousingHumanHuman Herpesvirus 2ImmuneImmune responseIn VitroInfectionKnowledgeLeadLibrariesMHC Class I GenesMacacaMembrane ProteinsMorphologic artifactsMulti-Drug ResistanceNatural Killer CellsOralPapillomavirusPathogenesisPatientsPersonsPharmaceutical ChemistryPharmaceutical PreparationsPhasePhosphotransferasesPlayPoxviridaePreclinical Drug EvaluationPrincipal InvestigatorProceduresPropertyProteinsRegulationResearchResistanceRiskRoleSIVScientistSpecificityStagingStructureSurfaceTestingTherapeutic IndexTimeToxic effectTriageUnited StatesValidationVendorViral AntigensViral PathogenesisViral ProteinsVirusVirus ReplicationWorkbasecell killingcombatcytotoxicitydrug developmentdrug discoverydrug resistant virusexperienceimmune functionimprovedin vitro activityin vitro testingin vivoinhibitor/antagonistkillingslead seriesnef Proteinnoveloperationphase 1 studypre-clinicalprogramsreceptorresistant strainresponsescaffoldscreeningsmall moleculesmall molecule librariessrc-Family Kinasessuccess
中文摘要
描述(由申请人提供):HIV诱导的HLA I类下调抑制剂多项研究表明,HLA I类(MHC-I)下调在HIV感染中起重要作用。病毒蛋白Nef诱导MHC-I下调并干扰病毒抗原的呈递,使hiv感染的细胞对cd8阳性ctl的杀伤不那么敏感。感染了缺乏这种活性的SIV的猕猴迅速恢复了这种能力
英文摘要
DESCRIPTION (provided by applicant): Inhibitors of HIV-induced downregulation of HLA class I Multiple studies suggest that downmodulation of HLA class I (MHC-I) plays an important role in HIV infection. The viral protein Nef induces MHC-I downmodulation and interferes with the presentation of viral antigens, making HIV-infected cells less sensitive to killing by CD8-positive CTLs. Macaques infected with SIV deficient in this activity rapidly restore the ability to
eliminate MHC-I. The mechanism by which Nef downmodulates MHC-I has been extensively investigated, however, despite its important role in pathogenesis this activity remains to be targeted for antiviral development. Further highlighting the importance of this function in immune evasion, interference with antigen presentation has also been recognized in many herpesviruses, poxviruses, papillomaviruses and adenoviruses. We propose screening a library of small molecules to identify inhibitors of the HIV-induced MHC-I downmodulation. A high content screen has been fully optimized and preliminary findings from a test pilot of 3,440 small-molecules have validated the assay and identified small-molecules blocking this promising target. Our results demonstrate proof-of-concept that potent and specific interference of MHC-I downmodulation with small molecules is possible. We propose the following aims: (1) to screen a library of 46,280 drug-like molecules composed of highly diverse structures, including molecules selected to target kinases, and other compounds known to be pharmacologically active (Lopac library); (2) to validate and characterize the potency, specificity and toxicity of hts, and; (3) to identify compounds that enhance the ability of CTLs to kill HIV- infected cells. We wil use a multi-modal HTS assay with multiple built-in controls to simultaneously confirm hits in primary screens and eliminate false positives with poor toxicity profiles, and other hits blocking HIV infection by known mechanisms. Success in this Phase I application will be defined by identifying one or more bona fide lead series of drug-like compounds with EC50s below 5¿M, minimal cytotoxicity (CC50 at least 30-fold greater than EC50), and the ability to sensitize HIV-infected cells to CTL killing. In a Phase II proposal, chemical leads from this screen will be selected for medicinal chemistry SAR optimization for potency, specificity and oral bioavailability. We wil further study the mechanism of action, characterize drug-resistant strains,
ases the potential for antagonism with approved antiretrovirals, and evaluate cross-resistance with other drugs. Additionally, a selected number of compounds will be tested in a small-animal model of HIV infection that recapitulates the virus-specific CTL responses. Compounds with improved profiles and characterized mechanism of action will be advanced into preclinical development studies to support future human trials. Administration of antivirals inhibiting MHC-I downmodulation may lengthen the time required before initiation of HAART therapy, or alternatively, in combination with other drugs may enhance their antiviral effect by improving the patient's immune response against the virus. These studies will constitute the foundation of a drug discovery program that may lead to first-in-class drugs of a novel family of antivirals with the potential for broader activity against other viruses. PHS 398/2590 (Rev. 06/09) Page Continuation Format Page
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Screen to Identify Arenavirus Inhibitors
-
批准号:8529177
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2013
-
负责人:JUAN LAMA
-
依托单位:
Novel Screen to Identify Arenavirus Inhibitors
-
批准号:8605165
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:JUAN LAMA
-
依托单位:
Inhibitors of HIV-induced downregulation of HLA class I
-
批准号:8410864
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:JUAN LAMA
-
依托单位:
An immune-based approach for HIV eradication
-
批准号:8924889
-
项目类别:
-
资助金额:$110.8万
-
财政年份:2012
-
负责人:JUAN LAMA
-
依托单位:
An immune-based approach for HIV eradication
-
批准号:9031713
-
项目类别:
-
资助金额:$122.64万
-
财政年份:2012
-
负责人:JUAN LAMA
-
依托单位:
An immune-based approach for HIV eradication
-
批准号:9223640
-
项目类别:
-
资助金额:$66.56万
-
财政年份:2012
-
负责人:JUAN LAMA
-
依托单位:
Small-molecule inhibitors of HIV-induced receptor downmodulation
-
批准号:8052156
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2010
-
负责人:JUAN LAMA
-
依托单位:
Targeting HIV-1 Envelope glycoprotein incorporation
-
批准号:7685833
-
项目类别:
-
资助金额:$21.84万
-
财政年份:2009
-
负责人:JUAN LAMA
-
依托单位:
Small-molecule inhibitors of HIV-induced receptor downmodulation
-
批准号:7754471
-
项目类别:
-
资助金额:$29.69万
-
财政年份:2009
-
负责人:JUAN LAMA
-
依托单位:
Fusion assay of the HIV-induced CD4 down-modulation
-
批准号:7140590
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2005
-
负责人:JUAN LAMA
-
依托单位:
Fusion assay of the HIV-induced CD4 down-modulation
-
批准号:7006159
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2005
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6020275
-
项目类别:
-
资助金额:$19.67万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6634335
-
项目类别:
-
资助金额:$24.1万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6706920
-
项目类别:
-
资助金额:$3.98万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6515839
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6797034
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6616260
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6653748
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6984006
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
ROLE OF CD4 DOWNMODULATION DURING HIV INFECTION
-
批准号:6362859
-
项目类别:
-
资助金额:$20.31万
-
财政年份:2000
-
负责人:JUAN LAMA
-
依托单位:
海外基金